Fulvestrant (FUL) as first-line therapy in HR1ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

被引：0
|
作者：
Pronzato, P. [1 ]
Mustacchi, G. [2 ]
Riccardi, F. [3 ]
Turletti, A. [4 ]
Michelotti, A. [5 ]
Natoli, C. [6 ]
Livi, L. [7 ]
Del Mastro, L. [8 ]
Donadio, M. [9 ]
Garrone, O. [10 ]
Giordano, M. [11 ]
De laurentiis, M. [12 ]
Marchetti, P. [13 ]
Montemurro, F. [14 ]
Romagnoli, E. [15 ]
De Placido, S. [16 ]
Biganzoli, L. [17 ]
Cazzaniga, M. [18 ]
机构：
[1] ASST Monza, Genoa, Italy
[2] Univ Trieste, Trieste, Italy
[3] Azienda Osped Rilievo Nazl Antonio Cardarelli, UOSC Oncol, Naples, Italy
[4] Osped Martini ASLTO 1 Torino, Turin, Italy
[5] Osped S Chiara Pisa, UO Oncol Med 1, Pisa, Italy
[6] SS Annunziata Hosp, Oncol Unit, Chieti, Italy
[7] AOU Careggi, Radioterapia Oncol, Florence, Italy
[8] IRCCS SAN MARTINO IST Ist Nazl Ric Canc, SS Sviluppo Terapie Innovat, Genoa, Italy
[9] AOU Citta Salute & Sci, SSD Oncol Senol, Turin, Italy
[10] AOS Croce & Carle Osped Insegnamento, Oncol Med, Cuneo, Italy
[11] Osped St Anna Como, Oncol, Como, Italy
[12] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[13] Sapienza Univ Roma, Oncol Med, Rome, Italy
[14] Candiolo Canc Inst FPO IRCCS, Direzione Oncol Clin Invest, Turin, Italy
[15] Osped Macerata, UOC Oncol, Macerata, Italy
[16] Univ Napoli Federico II, Dipartimento Med Clin & Chirurg, Oncol, Naples, Italy
[17] Osped Santo Stefano, USL Toscana Ctr, Oncol Med, Prato, Italy
[18] ASST Monza, Monza, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C25
引用
收藏
页数：1
相关论文
共 37 条
  • [21] Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Sellami, Dalila
    El-Hashimy, Mona
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    Baselga, Jose
    CANCER RESEARCH, 2018, 78 (04)
  • [22] E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2-BC): Results from a phase I study dose-expansion part
    Yonemori, K.
    Miyoshi, Y.
    Yasojima, H.
    Watanabe, J.
    Takano, T.
    Shimomura, A.
    Tokunaga, E.
    Mukohara, T.
    Naoi, Y.
    Okumura, S.
    Suzuki, T.
    Otake, Y.
    Matsuoka, D.
    Takase, T.
    Semba, T.
    Ishiguro, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S352 - S353
  • [23] GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)
    Albanell, J.
    Martinez, M. T. M.
    Ramos, M.
    O'Connor, M.
    De la Cruz-Merino, L.
    Santaballa Bertran, A.
    Martinez-Janez, N.
    Moreno, F.
    Fernandez Perez, I.
    Alarcon Company, J.
    Virizuela Echaburu, J. A.
    De la Haba Rodriguez, J.
    Sanchez-Rovira, P.
    Gonzalez-Cortijo, L.
    Margeli Vila, M.
    Sanchez Munoz, A.
    Garau Llinas, I.
    Casas, M.
    Bezares Montes, S.
    Rojo Todo, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S1151 - S1151
  • [24] Alpelisib (ALP) plus fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.
    Juric, Dejan
    Rugo, Hope S.
    Reising, Albert
    Ma, Chong
    Ciruelos, Eva M.
    Loibl, Sibylle
    Singer, Christian F.
    Sohn, Joohyuk
    Campone, Mario
    Conte, Pierfranco
    Iwata, Hiroji
    Ghaznawi, Farhat
    Miller, Michelle Kristine
    Taran, Tetiana
    Su, Fei
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Martin, Miguel
    Loibl, Sibylle
    Hyslop, Terry
    de la Haba-Rodriguez, Juan
    Aktas, Bahriye
    Cirrincione, Constance
    Carrasco, Eva Maria
    Mehta, Keyur
    Barry, William Thomas
    Morales, Serafin
    Carey, Lisa A.
    Saenz, Jose Angel Garcia
    Partridge, Ann
    Martinez, Noelia
    Hahn, Olwen Mary
    Winer, Eric P.
    Guerrero, Angel
    Hudis, Cliff
    Casas, Maribel
    Dickler, Maura N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
    Lueftner, Diana
    Brucker, Cosima
    Decker, Thomas
    Fasching, Peter A.
    Goehler, Thomas
    Jackisch, Christian
    Janssen, Jan
    Koehler, Andreas
    Luedtke-Heckenkamp, Kerstin
    Van Mackelenbergh, Marion
    Marme, Frederik
    Nusch, Arnd
    Rautenberg, Beate
    Reimer, Toralf
    Schmidt, Marcus
    Weide, Rudolf
    Wimberger, Pauline
    Nabieva, Naiba
    Roos, Christian
    Woeckel, Achim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA
    Decker, Thomas
    Brucker, Cosima
    Engel, Anne
    Fasching, Peter A.
    Goehler, Thomas
    Jackisch, Christian
    Janssen, Jan
    Koehler, Andreas
    Luedtke-Heckenkamp, Kerstin
    Lueftner, Diana
    van Mackelenbergh, Marion
    Marme, Frederik
    Nusch, Arnd
    Rautenberg, Beate
    Reimer, Toralf
    Schmidt, Marcus
    Weide, Rudolf
    Wimberger, Pauline
    Roos, Christian
    Woeckel, Achim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Treatment patterns and clinical outcomes among patients (pts) with HER2-advanced breast cancer (ABC) and somatic BRCA1/2 mutation(s) (sBRCA1/2mut): Results from a US real-world study
    Obeid, Elias
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Arondekar, Bhakti
    Hitchens, Abigail
    Arruda, Lillian Shahied
    Niyazov, Alexander
    CANCER RESEARCH, 2021, 81 (04)
  • [29] Treatment patterns and clinical outcomes among patients (pts) with HER2-advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): results from a US real-world study
    Obeid, Elias
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Arondekar, Bhakti
    Hitchens, Abigail
    Arruda, Lillian Shahied
    Niyazov, Alexander
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
    Steger, Guenther G.
    Egle, Daniel
    Bartsch, Rupert
    Pfeiler, Georg
    Petru, Edgar
    Greil, Richard
    Helfgott, Ruth
    Marth, Christian
    Oehler, Leopold
    Hubalek, Michael
    Lang, Alois
    Tinchon, Christoph
    Haslbauer, Ferdinand
    Redl, Andreas
    Hock, Karin
    Hennebelle, Mathias
    Mraz, Bernhard
    Gnant, Michael
    BREAST, 2020, 50 : 64 - 70
1234